Ontology highlight
ABSTRACT: Background
Malaria in Yemen is mainly caused by Plasmodium falciparum and 25% of the population is at high risk. Sulfadoxine-pyrimethamine (SP) had been used as monotherapy against P. falciparum. Emergence of chloroquine resistance led to the shift in anti-malarial treatment policy in Yemen to artemisinin-based combination therapy, that is artesunate (AS) plus SP as first-line therapy for uncomplicated malaria and artemether-lumefantrine as second-line treatment. This study aimed to screen mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) genes associated with SP resistance among P. falciparum population in Hadhramout governorate, Yemen.Methods
Genomic DNA was extracted from dried blood spots of 137 P. falciparum isolates collected from a
SUBMITTER: Bamaga OA
PROVIDER: S-EPMC4688959 | biostudies-literature | 2015 Dec
REPOSITORIES: biostudies-literature